Ingingo iyo ari yo yose yiswe Retatrutid Dosage Guide & Titration Gahunda 2026 igomba gutangirana nigisobanuro kimwe cyingenzi: mumwaka wa 2026, retatrutide iracyari iperereza rimwe mubyumweru peptide yatewe inshinge, ntabwo ari imiti yemewe ifite ikirango rusange. Lilly abisobanura nk'imisemburo itatu ya reseptor agonist yibasira GIP, GLP-1, na glucagon reseptors, akavuga ko byemewe n'amategeko gusa abitabiriye ibizamini by’amavuriro. Lilly Medical avuga kandi ko retatrutide itemewe muri iki gihe cyangwa ibihugu byose. Ibyo bivuze ko 'dosiye yerekana neza ' uyumunsi ntabwo ari urupapuro rwabigenewe rwo gukoresha abaguzi, ahubwo ni incamake yitonze yingengabihe ya titre, dosiye igenewe, hamwe nuburyo bwo kwihanganira bukoreshwa mubushakashatsi bwubuvuzi. Kubasomyi bakurikira iterambere rya peptide, imigendekere yamasoko, cyangwa amakuru yibicuruzwa bya tekiniki, iryo tandukaniro rifite akamaro kuko ikiganiro mumwaka wa 2026 kivuga kubijyanye no kwiyongera kwa dose, ntabwo ari ugukoresha wenyine.
Retatrutid yimutse irenze ibyiciro byambere kandi muri gahunda yagutse yicyiciro cya 3. Lilly yatangaje muri Werurwe 2026 ko ubushakashatsi bwayo bwa mbere bwo mu cyiciro cya 3 cyo mu bwoko bwa 2, TRANSCEND-T2D-1, bwujuje ibyingenzi kandi by'ingenzi byisumbuyeho, mu gihe mbere icyiciro cya 3 cyasomwe kijyanye n'umubyibuho ukabije nka TRIUMPH-4 cyari kimaze kwerekana ibisubizo bikomeye byo kugabanya ibiro. Nubwo bimeze bityo ariko, Lilly akomeje gusobanura retatrutide nkiperereza, kandi ubushakashatsi burimo gukorwa buracyasuzuma uburyo dosiye zitandukanye zikora mubyibushye, diyabete yo mu bwoko bwa 2, osteoarthritis yo mu ivi, kubuza ibitotsi gusinzira, ingaruka z'umutima n'imitsi, ibisubizo by'impyiko, hamwe n'indwara ziterwa n'umwijima.
Ibi bifite akamaro kubiganiro bya dosiye kuko ntagipimo kimwe cyemewe cyo kubungabunga. Ahubwo, ishusho ya 2026 yubatswe hafi ya dosiye Lilly arimo gufata cyane mugice cya 3: 4 mg, mg 9, na mg 12, byose byatanzwe rimwe mubyumweru nyuma yuburyo buhoro buhoro.
Mubiganiro bya peptide kumurongo, ibipimo bya dosiye akenshi byoroha mubishushanyo bisa nkibikemutse kuruta siyanse. Hamwe na retatrutide, ibyo birayobya. Lilly aragabisha yeruye ko molekile itigeze isuzumwa cyangwa ngo yemezwe n'ikigo icyo ari cyo cyose gishinzwe kugenzura kandi akavuga ko nta muntu ukwiye gutekereza gufata ikintu icyo ari cyo cyose kivuga ko ari retatrutide hanze y'urubanza rwatewe inkunga na Lilly. FDA kandi yihanangirije abakiriya ku bicuruzwa bitemewe birimo retatrutide yagurishijwe hamwe n’amabwiriza yo kugabanya, avuga ko ibicuruzwa nk'ibyo bishobora kuba bitujuje ubuziranenge kandi bishobora kwangiza.
Rero, kubasomyi ba SEO hamwe nabaguzi binganda, gushiraho inshingano ni iyi: dossi ya retatrutide mumwaka wa 2026 bivuga ikoreshwa ryiperereza ryamavuriro, ntabwo ari ugucuruza cyangwa gufata imiti isanzwe. Ibyo birasobanura kandi impamvu amakuru yizewe aturuka kumurongo wa Lilly, ibikoresho byubuvuzi bya Lilly, urutonde rwa ClinicalTrials.gov, hamwe nurungano rwasuzumwe n’ibitabo byageragejwe aho kuba ibicuruzwa byatanzwe n'abacuruzi.
Uburyo bwiza bwo gufata neza muri 2026 buva mubikoresho bya Lilly. Muri TRANSCEND-T2D-1, abitabiriye amahugurwa batoranijwe kuri retatrutide batangiriye kuri mg 2 rimwe mu cyumweru kandi biyongera muburyo bwintambwe buri byumweru bine kugeza bageze kuntego bashinzwe. Lilly yasobanuye ihame ryibanze ryo kuzamura muri gahunda ya TRIUMPH umubyibuho ukabije.
Ibyo bitanga ikigeragezo gifatika gishingiye kumutwe:
Intego |
Icyumweru 1-4 |
Icyumweru 5–8 |
Icyumweru 9-12 |
Icyumweru 13-16 |
Icyumweru cya 17 |
4 mg |
2 mg |
4 mg |
kubungabunga |
- |
- |
9 mg |
2 mg |
4 mg |
6 mg |
9 mg |
kubungabunga |
12 mg |
2 mg |
4 mg |
6 mg |
9 mg |
12 mg |
Iyi mbonerahamwe ivuga muri make gahunda yo gutera intambwe Lilly yatanze raporo yicyiciro cya 3. Muyandi magambo, akaboko ka mg 4 gakoresha intambwe imwe yo kuzamuka nyuma yicyiciro cyo gutangira, ukuboko kwa mg 9 gukoresha urwego rwa dose inshuro eshatu mbere yo kubungabunga, naho 12 mg ikoresha bine. Igishushanyo cyubatswe neza kugirango gitezimbere kwihanganira aho guhubuka abitabiriye kwerekanwa cyane.
Inyigo ya Retatrutid yo mu cyiciro cya 2 ikomeje kuba ingirakamaro kuko yerekanaga impamvu guhitamo ibipimo byabaye ikibazo nyamukuru. Lilly yatangaje ko ku bantu bakuru bafite umubyibuho ukabije cyangwa umubyibuho ukabije udafite diyabete, retatrutide yageze kuri 17.5% bivuze kugabanya ibiro mu byumweru 24 na 24.2% mu byumweru 48. Ikinyamakuru New England Journal of Medicine cyasohoye kandi cyerekana ko ubushakashatsi bwakoze ubushakashatsi ku ntwaro nyinshi za retatrutide aho kuba inzira imwe ihamye, harimo amatsinda yo hasi kandi menshi.
Icyiciro cya 2 cyahindutse mubyukuri nukwumva isoko kubyerekeye dose-reaction. Amaboko maremare menshi yabyaye ibimenyetso bikomeye byo kugabanya ibiro, ariko ingaruka zo munda nazo zibanze ku kuzamuka kwa dose. Iyo ni imwe mu mpamvu nyuma yiterambere ryerekeje kuri filozofiya yuburyo butandukanye aho gufata retatrutide nkibicuruzwa byoroshye-byuzuye.
Ikosa risanzwe mubucuruzi bwa peptide nukwibanda gusa kumupanga wanyuma. Hamwe na retatrutide, inzira igana dose ningirakamaro nkumubare ubwawo. Mu mwaka wa 2026 Lilly yasohoye icyiciro cya 3 cya diyabete, ibintu byakunze kugaragara ni isesemi, impiswi, no kuruka, Lilly yavuze ko byabayeho cyane cyane mu gihe cyo kwiyongera. Ibyo bisobanuro birakomeye kuko bisobanura logique inyuma ya 2 mg yo gutangira ikigereranyo hamwe nibyumweru bine intambwe-ndende.
Imiterere imwe igaragara muri TRIUMPH-4. Lilly yatangaje ingaruka mbi zo mu gifu nko kugira isesemi, impiswi, kuribwa mu nda, kuruka, no kugira ubushake bwo kurya, ndetse na dysesthesia muri bamwe mu bitabiriye amahugurwa. Guhagarika imirimo kubera ibintu bibi byari hejuru mu matsinda 9 mg na 12 mg kuruta umwanya wa Lobo, Lilly yavuze ko iryo hagarikwa rifitanye isano rya bugufi na BMI y'ibanze, hamwe no guhagarika bimwe bifitanye isano no guta ibiro bikabije.
Ingano eshatu zigamije kugaragara muri 2026 ni mg 4, mg 9, na mg 12. Ntabwo bose bagaragara muri buri baturage biga muburyo bumwe. Muri TRANSCEND-T2D-1, Lilly yatangaje ko A1C yagabanutse mu byumweru 40 bya -1.7% kuri mg 4, -2.0% kuri mg 9, na -1.9% kuri mg 12, mu gihe kugabanya ibiro by’umubiri byari -11.5%, -15.5%, na -16.8%.
Mubikorwa byibanda ku mubyibuho ukabije Icyiciro cya 3, Lilly yashimangiye cyane dosiye yo hejuru cyane. Muri TRIUMPH-4, amatsinda 9 mg na 12 mg yabyaye bivuze kugabanya ibiro -26.4% na -28.7% mubyumweru 68 kubantu bakuze bafite umubyibuho ukabije cyangwa umubyibuho ukabije hamwe na osteoarthritis. Lilly yavuze kandi ko ibisubizo by'inyongera bya TRIUMPH biteganijwe mu 2026 birimo urugero rwo kubungabunga mg 4 hamwe na 9 mg na 12 mg bimaze kugaragara muri ubwo bushakashatsi.
Ufatiye hamwe, aya makuru yerekana logique yiterambere 2026 aho mg 4 zishobora kuba uburyo bwo kubungabunga imbaraga nke, mugihe mg 9 na mg 12 aribwo buryo bwo gukora iperereza bukabije burimo kwigwa aho ingaruka nini zo kugabanya ibiro ari zo nkuru. Nibisobanuro bishingiye ku gishushanyo mbonera no hejuru yamakuru, ntabwo ari itegeko ryemewe.
Kubasomyi bagerageza kumva ingengabihe ya retatrutide mumagambo asobanutse, icyitegererezo cyikigereranyo kirahuye neza:
Inyigisho nyinshi zitinze zitangirana na mg 2 rimwe mucyumweru.
Igipimo cyiyongera buri byumweru bine, mubisanzwe bigenda munzira ndende nka mg 4, mg 6, na mg 9 munzira igana kuntego yo hejuru.
Intego yashizweho imaze kugerwaho, abitabiriye amahugurwa baguma aho mugihe gisigaye cyo kuvura keretse protocole yemerera guhagarika cyangwa guhindura dose. Ibikoresho bya Lilly bisobanura ko ari intambwe yo kuzamuka kugera ku ntego ikurikirwa no gukomeza kuvurwa kuri urwo rwego.
Retatrutid ni imwe mu peptide ya metabolike ikurikiranwa cyane mu 2026, ariko inkuru ya dosiye iracyari inkuru yiterambere, ntabwo ari iy'ubucuruzi yarangiye. Ibimenyetso bikomeye biboneka uyumunsi byerekana gahunda yo gutera inshinge buri cyumweru itangirira kuri mg 2, ikiyongera buri byumweru bine, kandi igamije kugenera dosiye nka mg 4, mg 9, cyangwa mg 12 bitewe na protocole. Icyiciro cya 2 nicyiciro cya 3 bifasha gusobanura impamvu iyo miterere ibaho: dosiye ndende isa nkaho itwara ibimenyetso bifatika byerekana imbaraga, mugihe igihe cyo kuzamuka ariho kwihanganira biba ngombwa. Dukurikije uko tubibona, ibyo bituma gusobanura neza bifite agaciro kuruta gusebanya. Kubasomyi, amakipe ashakisha, hamwe nabaguzi binganda bashaka kumva ibikoresho bya retatrutide, ibisobanuro bya peptide, hamwe nubutaka bwagutse bwa tekinike muburyo bufite ishingiro, birakwiye ko twiga byinshi kuri Cocer Peptides Co, Ltd. no kuganira ku ngingo duhereye ku bimenyetso bifatika, ibicuruzwa-amakuru aho kuba imitekerereze ya shortcut.
Oya. Lilly avuga ko retatrutide ari iperereza, byemewe n'amategeko binyuze mu bigeragezo byayo by’amavuriro, kandi bitemewe n’inzego zibishinzwe.
Icyiciro gisobanutse neza Icyiciro cya 3 cyatanzwe na Lilly gitangira abitabiriye mg 2 mg rimwe mucyumweru, hagakurikiraho kwiyongera-intambwe buri byumweru bine kugeza igihe igipimo cyagenwe kigeze.
Lilly yatangaje ibintu bibi cyane cyane isesemi, impiswi, no kuruka, byabaye cyane cyane mugihe cyo kwiyongera kwinshi, niyo mpamvu gahunda yo kugenda buhoro buhoro igaragara nkibyingenzi kwihanganira.
Yego. ClinicalTrials.
